The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....

Timber Pharmaceuticals to be Acquired by LEO Pharma Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value RightsTotal Transaction Value of up to $36 millionTransaction Expected to Close...

Klox Technologies and LEO Pharma set up company for BioPhotonic in dermatology LAVAL, Quebec and BALLERUP, Denmark, March 06, 2017 (GLOBE NEWSWIRE) -- Klox Technologies Inc. (‘Klox’) and LEO Pharma A/S (‘LEO Pharma’) to establish a jointly owned company to further develop and...